Alzheimer Disease
1,744
317
408
857
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
255 trials with published results (15%)
Research Maturity
857 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.9%
121 terminated out of 1744 trials
87.6%
+1.1% vs benchmark
8%
148 trials in Phase 3/4
30%
255 of 857 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 857 completed trials
Clinical Trials (1744)
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Impact of COVID-19 Vaccines on Cerebrovascular Health
Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Technology and Family Thriving Study
Study of Repetitive Behaviors in Alzheimer's Disease
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
Ozanimod in Patients With Alzheimer's Disease
COMMETS- Combination MCI Metabolic Syndrome
Community-based Brain Health Program to Address Dementia Risk
Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers
Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease
National Bank Alzheimer
Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)
Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease
Falls: A Marker of Preclinical AD
Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)